1. Home
  2. WTMAU vs RVMDW Comparison

WTMAU vs RVMDW Comparison

Compare WTMAU & RVMDW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • WTMAU
  • RVMDW
  • Stock Information
  • Founded
  • WTMAU N/A
  • RVMDW N/A
  • Country
  • WTMAU
  • RVMDW United States
  • Employees
  • WTMAU N/A
  • RVMDW 490
  • Industry
  • WTMAU
  • RVMDW
  • Sector
  • WTMAU
  • RVMDW
  • Exchange
  • WTMAU NYSE
  • RVMDW Nasdaq
  • Market Cap
  • WTMAU N/A
  • RVMDW N/A
  • IPO Year
  • WTMAU N/A
  • RVMDW N/A
  • Fundamental
  • Price
  • WTMAU $11.27
  • RVMDW $0.18
  • Analyst Decision
  • WTMAU
  • RVMDW
  • Analyst Count
  • WTMAU 0
  • RVMDW 0
  • Target Price
  • WTMAU N/A
  • RVMDW N/A
  • AVG Volume (30 Days)
  • WTMAU N/A
  • RVMDW N/A
  • Earning Date
  • WTMAU N/A
  • RVMDW N/A
  • Dividend Yield
  • WTMAU N/A
  • RVMDW N/A
  • EPS Growth
  • WTMAU N/A
  • RVMDW N/A
  • EPS
  • WTMAU N/A
  • RVMDW N/A
  • Revenue
  • WTMAU N/A
  • RVMDW N/A
  • Revenue This Year
  • WTMAU N/A
  • RVMDW N/A
  • Revenue Next Year
  • WTMAU N/A
  • RVMDW N/A
  • P/E Ratio
  • WTMAU N/A
  • RVMDW N/A
  • Revenue Growth
  • WTMAU N/A
  • RVMDW N/A
  • 52 Week Low
  • WTMAU N/A
  • RVMDW N/A
  • 52 Week High
  • WTMAU N/A
  • RVMDW N/A
  • Technical
  • Relative Strength Index (RSI)
  • WTMAU 54.81
  • RVMDW N/A
  • Support Level
  • WTMAU N/A
  • RVMDW N/A
  • Resistance Level
  • WTMAU $11.60
  • RVMDW N/A
  • Average True Range (ATR)
  • WTMAU 0.00
  • RVMDW 0.00
  • MACD
  • WTMAU -0.00
  • RVMDW 0.00
  • Stochastic Oscillator
  • WTMAU 0.00
  • RVMDW 0.00

About WTMAU WELSBACH TECHNOLOGY METALS ACQ CORP

Welsbach Technology Metals Acquisition Corp is a blank check company.

About RVMDW Revolution Medicines Inc. Warrant

Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs.

Share on Social Networks: